Pregnancy and Peptide Use

Absolute Contraindications

Pregnancy represents an absolute contraindication for most peptide use. Approved peptide drugs say so on their labels; research peptides have no human pregnancy data at all. Our overview of contraindicated conditions explains how labels sort these.

During Pregnancy

Peptide	Status	Rationale
Tesamorelin (Egrifta WR)	Contraindicated (FDA label)	Hydrocephaly in offspring of treated rats
Semaglutide (Wegovy)	Label: discontinue when pregnancy is recognized	May cause fetal harm
Tirzepatide (Zepbound)	Label: discontinue when pregnancy is recognized	Human data insufficient
Bremelanotide (Vyleesi)	Label: discontinue if pregnancy is suspected	Fetal loss in dogs
All research peptides	No human data	Unknown fetal effects

During Breastfeeding

Compound	Label language
Egrifta WR	Mothers instructed not to breastfeed
Wegovy tablets	Breastfeeding not recommended
Zepbound	Low or undetectable in milk after one dose; no infant data
Vyleesi, research peptides	No milk data

Potential Risks

Known Concerns

Risk	Mechanism	Significance
Fetal development	Harm in rat and dog label studies	Major concern
Hormonal disruption	GH/IGF-1 effects	Theoretical
Unknown teratogenicity	No human data	Cannot rule out
Miscarriage	Theoretical	Unquantified

Specific Peptide Concerns

Peptide	Specific Risk	Evidence
GH secretagogues	Fetal growth effects	Theoretical
IGF-1	Growth dysregulation	Theoretical
BPC-157	Unknown fetal effects	One rat study found no fetal changes (2025 review); no human data

Planning for Pregnancy

Pre-Conception Period

As of October 2026, the Wegovy label says to discontinue semaglutide at least 2 months before a planned pregnancy because of its long half-life. The Zepbound label notes that tirzepatide can reduce oral contraceptive exposure and advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase. Vyleesi's label calls for effective contraception.

GLP-1 use around conception is an active research area. A 2024 JAMA Internal Medicine cohort of 938 exposed infants of women with type 2 diabetes found no clear rise in major birth defects compared with insulin, though the authors say confirmation is needed. For research peptides there are no washout data, and we found no source for the common "stop 3+ months before" figure.

For Men

We found no human data on whether a father's peptide use affects sperm or pregnancy outcomes.

After Pregnancy

No label gives a timeline for resuming research peptides; breastfeeding and plans for another pregnancy matter, and a clinician decides. Diabetes during pregnancy raises separate issues covered in our diabetes considerations.

Non-Drug Approaches

Nothing here is proven safe as a peptide substitute. Exercise and nutrition in pregnancy are areas for individual prenatal advice.

Resource	Role
OB/GYN	Primary pregnancy care
Dietitian	Nutritional support
Trainer (prenatal certified)	Exercise in pregnancy

Legal and Ethical Considerations

The four drugs above are prescription medicines; research peptides aren't approved for human use. A provider can only weigh prior use they know about.

What We Still Don't Know

Whether any research peptide affects human pregnancy or breast milk.
Whether GLP-1 findings in women with diabetes apply to weight-loss users.